The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype

Figures & data

Table 1 The baseline clinical data and analysis after stratification by frequent exacerbator phenotype

Parameters	Total (n=19)	Frequent exacerbator (n=5)	Nonfrequent exacerbator (n=14)	P-value
Age (years), mean (SD)	66.32 (7.06)	63.6 (5.08)	67.29 (7.56)	0.33
Female, n (%)	14 (73.68)	5 (100)	9 (64.29)	0.26
History of COPD (years), mean (SD)	10.21 (7.83)	10.4 (3.21)	10.14 (9.04)	0.95
History of smoking (pack-years), mean (SD)	33.05 (13.88)	40.4 (11.61)	30.43 (14.04)	0.17
sRAGE (pg/mL), mean (SD)	975.68 (399.31)	657.89 (437.88)	1,089.18 (330.25)	0.03
FEV1 (L), mean (SD)	0.91 (0.49)	0.54 (0.17)	1.04 (0.51)	0.05
FEV1 (%), mean (SD)	36.6 (17.11)	23.72 (5.91)	41.21 (17.55)	0.005
FVC (L), mean (SD)	1.94 (0.88)	1.48 (0.53)	2.11 (0.94)	0.09
FVC (%), mean (SD)	60.62 (20.92)	50.67 (14.74)	64.17 (22.08)	0.16
FEV1/FVC, mean (SD)	0.46 (0.12)	0.37 (0.05)	0.49 (0.13)	0.07
mMRC, stage, median (IQR)	3 (2.25–4)	4 (3.5–4)	3 (2.25–3.75)	0.28
BMI (kg/m^2), mean (SD)	26.16 (5.78)	22.42 (4.6)	27.5 (5.7)	0.09
Major comorbiditiesa
Ischemic heart disease, n (%)	8 (42.11)	3 (60)	5 (35.71)	0.6
Acute myocardial infarction in history, n (%)	4 (21.05)	1 (20)	3 (21.43)	1.0
Congestive heart failure, n (%)	7 (36.84)	2 (40)	5 (35.71)	1.0
Arterial hypertension, n (%)	14 (73.68)	5 (100)	9 (64.29)	0.26
GERD, n (%)	5 (26.32)	1 (20)	4 (28.57)	1.0
Obesity, n (%)	8 (42.11)	1 (20)	7 (50)	0.34

Note:

a According to available medical records and history.

Abbreviation: sRAGE, soluble receptor for advanced glycation end-products.

Figure 1 ROC curve for sRAGE in the identification of frequent exacerbator phenotype.

Note: The cutoff point presented best sum of specificity, and sensitivity presented in brackets was marked.
Abbreviations: ROC, receiver operating characteristic; sRAGE, soluble receptor for advanced glycation end-products.

Figure 2 Kaplan–Meier curves for the time to the subsequent exacerbation (days), stratified by the sRAGE value of 850.407 pg/mL.

Abbreviation: sRAGE, soluble receptor for advanced glycation end-products.